Aerovate Therapeutics (AVTE)
(Delayed Data from NSDQ)
$1.82 USD
-0.07 (-3.70%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $1.83 +0.01 (0.55%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVTE 1.82 -0.07(-3.70%)
Will AVTE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVTE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVTE
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
AVTE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AVTE
Aerovate Therapeutics to Explore Strategic Alternatives
The 3 Hottest Stock Downgrades From Last Week
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
Biotech Alert: Searches spiking for these stocks today
Aerovate Therapeutics discloses director purchase of $1.55M in common stock